Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a tumor-suppression mechanism, autophagy deficiency is common in tumors, which results in aberrant accumulation of p62 and activates p62-regulated pathways, such as activation of mTOR in nutrient sensing, and the activation of the Keap1-Nrf2 pathway for antioxidant stress, which are associated with cancer development.
|
31802896 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>Apc<sup>Min/+</sup></i> mice when infected with CR and <i>BLT1<sup>-/-</sup>;Apc<sup>Min/+</sup></i> mice, exhibited similar co-localization of p62 with LC3B and Dclk1 within the tumors.
|
31040926 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the role of p62 in tumour development depends on the interacting factors it recruits and its precise regulatory mechanism remains unclear.
|
30941888 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, we demonstrated that XIAP-enhanced tumor growth is dependent on depletion of p62 in vivo.
|
30275562 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Evidence has shown that p62 is upregulated in different cancers and promotes tumour growth, such as in liver cancer and lung cancer.
|
30793399 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Dynamic LC3B and p62 changes are suggested to be involved in gastric tumorigenesis and cancer progression.
|
31810936 |
2019 |
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Our data indicate that accumulation of p62 by impaired autophagic flux is involved in the activation of NRF2 and contributes to skin tumorigenesis due to chronic arsenite exposure.
|
31781319 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overall, our findings place Nrf2 and p62 as the key components of the mesenchymal subtype network, with implications to tumorigenesis and treatment resistance.
|
31444413 |
2019 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Co-localization of autophagy-related protein p62 with cancer stem cell marker dclk1 may hamper dclk1's elimination during colon cancer development and progression.
|
31040926 |
2019 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of p62 in cancer is controversial.
|
30793399 |
2019 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The integrative approach uncovered novel miRNA-gene networks (e.g., miR-146 and miR-34 regulating p62 and Beclin1 in autophagy) that might give new insights into the complex regulatory mechanisms of gene expression in AD and cancer.
|
31608105 |
2019 |
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, phosphorylation of KHK-A S80 and p62 S28 and nuclear accumulation of Nrf2 are positively correlated in human HCC specimens and with poor prognosis of patients with HCC.
|
31032410 |
2019 |
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, a recent study showed that the downregulation of p62 in hepatic stellate cells (HSCs) promotes hepatocellular carcinoma (HCC) development.
|
30793399 |
2019 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the levels of p62 also significantly decreased, and the cathepsin D levels increased, accompanied by increased turnover of Aβ and APP in Se-yeast-treated AD mice.
|
30043821 |
2018 |
Amyotrophic Lateral Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Remarkably, despite the large degree of heterogeneity, all cases of ALS have protein aggregates in the brain and spinal cord that are immunopositive for SOD1, TDP-43, OPTN, and/or p62.
|
29515358 |
2018 |
Amyotrophic Lateral Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we found elevated levels of high molecular weight ubiquitinated proteins and p62 in animals expressing ALS-causing genes with TBI, suggesting that TBI may lead to the defects in protein degradation pathways.
|
29432563 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, this work demonstrates that FliI functions as a checkpoint protein for selective autophagy in the crosstalk between FliI and p62-recruited cargoes, and its phosphorylation may serve as a prognostic marker for breast cancer.<b>Significance:</b> Flightless-I functions as a checkpoint protein for selective autophagy by interacting with p62 to block its recognition of LC3, leading to tumorigenesis in breast cancer.<i>Cancer Res; 78(17); 4853-64.©2018 AACR</i>.
|
29898994 |
2018 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Investigation of cancer-associated fibroblasts and p62 expression in oral cancer before and after chemotherapy.
|
29439841 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, we discuss the potential therapeutic implications of targeting p62 in cancer, considering its multifaceted roles in diverse cell types of the tumor microenvironment.
|
29702207 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Autophagic Regulation of p62 is Critical for Cancer Therapy.
|
29738493 |
2018 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression levels of p62 and autophagy related proteins were evaluated in two panels of human cancer cell lines by western blot.
|
29699801 |
2018 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This reveals a central role of adipocyte's p62 in the symbiotic adipose tissue-tumor collaboration that enables cancer metabolic fitness.
|
29634950 |
2018 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
High levels of P62 predict high tumor grade and high intensity of metastasis.
|
29383752 |
2018 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
DIRAS3 expression in GC was positively correlated with LC3B-II amount, and negatively with metastasis; DIRAS3 and p62 levels were independent prognostic factors in GC.
|
30043279 |
2018 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The results demonstrated that the overexpression of p62 protein was detected in 77.1% (54/70) samples, and the expression levels were significantly associated with tumor size (P=0.001), metastasis (P=0.036), clinical staging (P=0.003) and poor prognosis (P=0.0058).
|
29928361 |
2018 |